Comparative analysis of Nε-carboxymethyl-lysine and inflammatory markers in diabetic and non-diabetic coronary artery disease patients

Table 6 Logistic regression analysis of Nε-carboxymethyl-lysine for risk of diabetic coronary artery disease

Risk model	CML quartile (range) (group I, n; group II, n)	Exp (B)	95%CI (lower-upper)	Significance
Model 1: Unadjusted	CML first quartile (83.73-193.18 ng/mL) (group I, n =27; group II, n =23)	Ref	Ref	Ref
	CML second quartile (193.19-264.42 ng/mL) (group I, n = 16; group II, n = 34)	0.85	0.48-1.48	0.57
	CML third quartile (264.43-364.31 ng/mL) (group I, n = 23; group II, n = 27)	2.12	1.17-3.85	0.01
	CML fourth quartile (364.32-665.00 ng/mL) (group I, n = 34; group II, n = 16)	1.17	0.67-2.04	0.57
Model 2: Model 1 + age + sex + non-vegetarian diet + hypertension	CML first quartile (83.73-193.18 ng/mL)	Ref	Ref	Ref
	CML second quartile (193.19-264.42 ng/mL)	0.57	0.27-1.23	0.15
	CML third quartile (264.43-364.31 ng/mL)	3.05	1.31-7.06	0.01
	CML fourth quartile (364.32-665.00 ng/mL)	1.81	0.82-3.99	0.13
Model 3: Model 2+ total cholesterol + triglycerides + LDL-C + IL-6 + TNF-α	CML first quartile (83.73-193.18 ng/mL)	Ref	Ref	Ref
	CML second quartile (193.19-264.42 ng/mL)	0.84	0.35-2.02	0.70
	CML third quartile (264.43-364.31 ng/mL)	3.32	1.30-8.44	0.01
	CML fourth quartile (364.32-665.00 ng/mL)	2.49	1.03-6.04	0.04

Group I: Diabetic coronary artery disease patients; Group II: Non-diabetic coronary artery disease patients. CI: Confidence interval; CML: Nε-carboxymethyl-lysine; IL-6: Interleukin 6; LDL-C: Low-density lipoprotein; TNF-α: Tumor necrosis factor-alpha.